Streetbeat News

KTTA

Pasithea Therapeutics Corp.

https://www.pasithea.com

Industry

Biotechnology

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Open

3.42

Mkt cap

3.5M

Volume

22K

High

3.42

P/E Ratio

-0.23

52-wk high

17.40

Low

3.19

Div yield

N/A

52-wk low

3.19

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Theriva Biologics, Conduit Pharmaceuticals, and ENDRA Life Sciences were among the top gainers, while Windtree Therapeutics, Soligenix, and Kazia Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 12:06 pm

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced a $5 million private placement to fund next-gen cancer treatments. The offering includes 1.2 million shares at $4.10 each, with accompanying warrants. Proceeds will support working capital and corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 7:03 am

The Dow Jones index rose over 250 points, with Accenture reporting better-than-expected earnings and announcing a dividend increase and share repurchase. Telesis Bio, Pasithea Therapeutics, and Jabil saw significant stock price increases, while Concentrix, Ryde Group, and MDxHealth experienced declines.

Portfolio Pulse from Avi Kapoor

September 26, 2024 | 6:52 pm

Several health care stocks experienced significant price movements during Thursday's intraday session. Notable gainers included Pasithea Therapeutics, Telesis Bio, and Adaptive Biotechnologies, while Inventiva and Theriva Biologics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:31 pm

U.S. stocks rose with the Dow Jones up 200 points. Initial jobless claims fell, while crude oil prices dropped over 2%. Telesis Bio, Pasithea Therapeutics, and Adaptive Biotechnologies saw significant stock gains, while Concentrix, Ryde Group, and MDxHealth experienced declines.

Portfolio Pulse from Avi Kapoor

September 26, 2024 | 4:01 pm

U.S. stocks rose with the Nasdaq gaining over 1%, driven by Micron's strong Q4 results. Micron reported revenue of $7.75 billion and earnings of $1.18 per share, both beating estimates. Telesis Bio, Pasithea Therapeutics, and Fangdd Network saw significant stock price increases, while VS MEDIA, Ryde Group, and MDxHealth experienced declines.

Portfolio Pulse from Avi Kapoor

September 26, 2024 | 1:48 pm

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced positive data from its Phase 1 trial of PAS-004, leading to a significant surge in its stock price. The trial showed promising safety, tolerability, and pharmacokinetic results, with no adverse events reported. The stock rose by 71.70% on high trading volume.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 12:56 pm

Pasithea Therapeutics shares rose following positive data from its Phase 1 clinical trial of PAS-004, showing safety, tolerability, and preliminary efficacy.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:13 pm

Micron Technology reported better-than-expected Q4 results, boosting its stock by 17%. Telesis Bio's partnership with Beckman Coulter Life Sciences led to a 148% surge in its stock. Pasithea Therapeutics announced positive data from its Phase 1 trial, increasing its stock by 69%.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:59 am

Pasithea Therapeutics reported positive safety, tolerability, and preliminary efficacy data from its Phase 1 trial of PAS-004. A patient with stage 3 colon cancer showed stable disease with no adverse events, supporting the drug's potential as a MEK inhibitor.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 11:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.